2023-10-19 02:19:12
50-100% increase in antibody binding capacity, pH 4.0 elution efficiency, and NaOH stability compared to first-generation ligands.
Widening the technology gap to accelerate entry into the global antibody purification resin market
[바이오타임즈] Amicogen (CEO Park Cheol), which is leading the local production of essential biopharmaceutical component materials, announced on the 19th that it has succeeded in developing a ligand for next-generation antibody purification and completed two patent applications.
In the case of the existing first-generation antibody purification ligand, the antibody falls off between pH 2.5 and 3.5. At this time, the antibody eluted at low pH aggregates and precipitates, resulting in lower production yield and lower quality.
To solve this problem, Amicogen succeeded in developing a next-generation ligand that elutes in high yield at pH 4.0. With this patent application, we plan to further accelerate our entry into the global antibody purification resin market by widening the technological gap with our competitors.
Resin for antibody purification is made using a ligand that can bind to an antibody and a carrier that immobilizes the ligand. Ligands determine antibody binding capacity (Dynamic Binding Capacity (DBC)), elution yield, and alkali tolerance, which are key indicators of resin performance. DBC and elution efficiency indicate how high the yield of antibodies can be recovered, and alkali resistance indicates how well the antibody can withstand the alkaline components used to wash the resin.
As a result of improving the Protein A ligand by applying its ‘gene evolution’ technology, Amicogen developed a next-generation ligand with ▲50% increase in elution efficiency ▲100% increase in antibody binding ability ▲80% increase in alkali resistance at pH 4.0 compared to existing ligands. did. The higher the indicators, the higher the antibody recovery rate during the purification process, which is a key factor in reducing production costs.
Amicogen CEO Park Cheol said, “Cell culture technology for biopharmaceutical production is advancing day by day, while resin technology is slow,” adding, “By developing next-generation ligands with significantly improved key indicators of the ligand, we are increasing the purification yield and speed of our customers’ antibodies. “It is expected that it will greatly contribute to quality improvement,” he said. He added, “We are already commercializing the ligand and supplying it to domestic and foreign bio companies, and we plan to enter the 600 billion won ligand market in earnest in the future.”
Amicogen has been developing resins by internalizing ligand and carrier technology for the past 10 years and supplying them to bio ventures and small and medium-sized bio companies.
An Amicogen official said, “Resin is a key material that determines the production yield of biopharmaceuticals, and as the price competitiveness of new drugs as well as biosimilars has recently emerged, domestic bio companies are continuing to inquire about supply.” He added, “Our resin is already available. “Through customer testing, we have confirmed that our quality is higher than that of our competitors, and once the Yeosu resin factory is completed at the end of this year, we will be able to begin full-scale supply next year.”
[바이오타임즈=김수진 기자] [email protected]
© BioTimes. Reproduction and redistribution prohibited.
1697693331
#Amicogen #succeeds #developing #ligand #nextgeneration #antibody #purification